CIA
MYGN icon

Capital Impact Advisors’s Myriad Genetics MYGN Stock Holding History

Capital Impact Advisors’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-68,114
Closed -$2.32M – 290
2014
Q4 		$2.32M Hold
68,114
– – 1.09% 38
2014
Q3 		$2.63K Hold
68,114
– – ﹤0.01% 44
2014
Q2 		$2.65M Hold
68,114
– – 2% 2
2014
Q1 		$2.33M Hold
68,114
– – 1.88% 1
2013
Q4 		$1.43M Buy
+68,114
New +$1.72M 1.15% 37

Other funds holding MYGN

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BTS
BB&T Securities Richmond, Virginia $10.9B AUM 5.31% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
IAM
Iridian Asset Management Westport, Connecticut $247M AUM 20.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Capital Impact Advisors's MYGN Position: Q1 2015 in Review

Capital Impact Advisors sold out of Myriad Genetics (MYGN) in Q1 2015, closing a stake of 68,114 shares — an estimated $2.32M sold.

Capital Impact Advisors first reported a position in MYGN in Q4 2013 and held it in 5 quarters. The position peaked at $2.65M in Q2 2014. 251 funds tracked by Wall St. Rank hold MYGN as of Q1 2015.

  • Capital Impact Advisors reported no remaining Myriad Genetics position as of Q1 2015 after selling out during the quarter.
  • Capital Impact Advisors sold 68,114 Myriad Genetics shares in Q1 2015, an estimated $2.32M.
  • Capital Impact Advisors first reported a position in Myriad Genetics in Q4 2013 and held it in 5 quarters.
  • Capital Impact Advisors's Myriad Genetics position peaked at $2.65M in Q2 2014.
  • 251 funds tracked by Wall St. Rank held Myriad Genetics as of Q1 2015.

Based on Capital Impact Advisors's 13F filing for Q1 2015, filed 29 May 2015.